Levocetirizine Dihydrochloride Patent Expiration
Levocetirizine Dihydrochloride was first introduced by Chattem Inc Dba Sanofi Consumer Healthcare
Levocetirizine Dihydrochloride Patents
Given below is the list of patents protecting Levocetirizine Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xyzal Allergy 24hr | US8633194 | Pharmaceutical composition of piperazine derivatives | Oct 16, 2027 | Chattem Sanofi |
| Xyzal |
US5698558 (Pediatric) | Methods for treating allergic disorders using optically pure (-) cetirizine |
Jan 26, 2014
(Expired) | Chattem Sanofi |
| Xyzal | US5698558 | Methods for treating allergic disorders using optically pure (-) cetirizine |
Jul 26, 2013
(Expired) | Chattem Sanofi |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Levocetirizine Dihydrochloride's patents.
Latest Legal Activities on Levocetirizine Dihydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Levocetirizine Dihydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Jul, 2025 | US8633194 |
| Review Certificate Mailed | 16 Aug, 2021 | US8633194 |
| Review Certificate | 22 Jul, 2021 | US8633194 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Jul, 2021 | US8633194 |
| Termination or Final Written Decision | 09 Jun, 2020 | US8633194 |
| Request for Trial Granted Critical
| 15 Jul, 2019 | US8633194 |
| Petition Requesting Trial | 13 Dec, 2018 | US8633194 |
| Patent Issue Date Used in PTA Calculation Critical
| 21 Jan, 2014 | US8633194 |
| Recordation of Patent Grant Mailed Critical
| 21 Jan, 2014 | US8633194 |
| Issue Notification Mailed Critical
| 31 Dec, 2013 | US8633194 |
Levocetirizine Dihydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Levocetirizine Dihydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) | Bridgette Jones | NA |
RECRUITING
(Apr 1, 2026)
| PHASE3 |